Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Monte Rosa Therapeutics Inc shares valued at $9,174 were sold by Dunn Edmund on Jun 03 ’25. At $4.45 per share, Dunn Edmund sold 2,062 shares. The insider’s holdings dropped to 23,732 shares worth approximately $0.12 million following the completion of this transaction.
Also, Leo Chandra P. purchased 10,000 shares, netting a total of over 58,383 in proceeds. Following the buying of shares at $5.84 each, the insider now holds 10,000 shares.
Before that, Versant Venture Capital VI, L. had sold 89,990 shares from its account. In a trade valued at $869,240, the 10% Owner traded Monte Rosa Therapeutics Inc shares for $9.66 each. Upon closing the transaction, the insider’s holdings decreased to 89,990 shares, worth approximately $9.78 million.
As published in a research note from Wells Fargo on December 19, 2024, Monte Rosa Therapeutics Inc [GLUE] has been rated down from an Overweight to an Equal weight and the price target has been revised to $11 from $14. Analysts at Wedbush started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid February. As of January 03, 2023, Wells Fargo has increased its “an Equal weight” rating to a “an Overweight” for GLUE. Earlier on October 13, 2022, UBS initiated its rating. Their recommendation was “a Buy” for GLUE stock.
Analyzing GLUE Stock Performance
On last trading session, Monte Rosa Therapeutics Inc [NASDAQ: GLUE] rose 2.96% to $4.87. The stock’s lowest price that day was $4.64, but it reached a high of $4.88 in the same session. During the last five days, there has been a surge of approximately 4.51%. Over the course of the year, Monte Rosa Therapeutics Inc shares have jumped approximately 23.60%. Shares of the company reached a 52-week high of $7.46 on 01/03/25 and a 52-week low of $3.50 on 04/07/25.
Support And Resistance Levels for Monte Rosa Therapeutics Inc (GLUE)
According to the 24-hour chart, there is a support level at 4.71, which, if violated, would cause prices to drop to 4.56. In the upper region, resistance lies at 4.95. The next price resistance is at 5.04. RSI (Relative Strength Index) is 57.86 on the 14-day chart, showing neutral technical sentiment.
Is Monte Rosa Therapeutics Inc subject to short interest?
Stocks of Monte Rosa Therapeutics Inc saw a sharp rise in short interest on 2025-06-13 jumping by 0.48 million shares to 8.87 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 8.4 million shares. A jump of 5.37% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 19.34 of the overall float, the days-to-cover ratio (short ratio) jumped to 19.34.
